News
-
XOMA Reports Second Quarter 2011 Financial Results
8/8/2011
XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced its financial results for the second quarter and six months ended June 30, 2011 and provided a general business update.
-
Adeona Plans To Commercialize wellZin™ To Reduce Symptoms Of The Common Cold
8/1/2011
Adeona Pharmaceuticals, Inc. announced today that it has acquired exclusive access to two sets of clinical data demonstrating, with statistical significance, the safety and efficacy of a particular oral zinc formulation in reducing the duration and severity of symptoms associated with the common cold.
-
Penn Study Finds A Genetic Basis For Muscle Endurance In Animal Study
7/25/2011
Researchers at the Perelman School of Medicine at the University of Pennsylvania have identified a gene for endurance, or more precisely, a negative regulator of it.
-
inVentiv Health Completes PharmaNet Acquisition
7/15/2011
inVentiv Health, offering best-in-class clinical, commercial and consulting services to the healthcare industry, today announced it has completed the acquisition of PharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries.
-
Data From Phase 1 Study Of NKTR-181 Demonstrate Proof-Of-Concept For Nektar's Novel Opioid Analgesic Candidate
6/7/2011
Nektar Therapeutics (NASDAQ: NKTR) announced today positive interim data from an ongoing single-dose Phase 1 clinical trial evaluating NKTR-181, the company's novel mu-opioid analgesic candidate.
-
Adeona Announces Positive Alzheimer's Subgroup Analysis That Supports Additional Clinical Study Of Proprietary Zinc-Based Therapy
6/2/2011
Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced today positive findings based on further analyses from the clinical study evaluating reaZin along with near-term plans for its Alzheimer's disease program.
This website uses cookies to ensure you get the best experience on our website. Learn more